If someone is in the audience at the talk tomorrow, can they please ask Diwan-
(a) why it's taken him and NNVC fourteen years and an atrociously high 87 million bucks of shareholder bucks and counting, and not yet achieved a single IND filing for any candidate compound,
(b) if he now intends to lucratively (for himself and Theracour) in-license VZV in to NNVC without encumbrance from any CEO and in such new licensing agreement actually impose on himself strict milestones and timelines at Theracour and have monetary penalties built into the agreement for Theracour's unmet milestones on deliverables and timelines to NNVC ,
(c) why he is doing even more non-GLP safety/ tox studies, expending yet more money and time rather than cut to the chase and do the GLP-studies (given that several non-GLP studies on Herpecide candidates in the past two years have shown them safe and benign),
(d) Why it is taking him at Theracour so long to scale up to GLP levels of pure drug candidate requirements, and if the compound is so difficult and time-consuming to prepare in good enough quality, it can even be commercially viable,
(e) what he plans to do to bring in non-toxic financing to sustain NNVC operations to an IND and Phase 1 clinical trial stage, so NNVC does not go belly-up in the interim, with the technology and IP then "conveniently" reverting entirely favorably to him and Theracour, and
(f) what he and his fellow NNVC Board of Directors are actively doing to deal with increasing questions of very serious conflicts of interest involving Anil and Theracour from shareholders, given that was the primary cited reason for Dr. Milton Boniuk's departure from the Board in his resignation letter. |
